Analysis and prognostic significance of tumour immune infiltrates and immune microenvironment of m6A-related IncRNAs in patients with gastric cancer

Jiarong Huang¹², Jinxuan Song², xiangyu Li², Shuangfei Liu³, Wentao Huang², Ziyi Shen², Yan Cheng⁴, Shien Kou⁴, Zhenguo Gao¹, Yunhong Tian¹* and Jiani Hu⁵

Abstract
Background: Studies have shown that long noncoding RNAs and N6-methyladenosine play important roles in gastric cancer. The purpose of this study was to determine the correlation and prognostic value of m6A-related IncRNAs and immune infiltration in gastric cancer.

Methods: We downloaded the clinically related information and RNA-Seq transcriptome data of gastric cancer patients from the TCGA database. Univariate Cox regression analysis and Pearson analysis were used to screen out m6A-related IncRNAs. Consensus cluster analysis was used to divide the sample into two clusters, and LASSO analysis and Cox regression analysis were used to construct a risk scoring model.

Results: A total of 25 IncRNA expression profiles were screened, and gastric cancer patients were divided into different subtypes. Cluster 2 had a better prognosis, but its stromal score, ESTIMATE score and immune score were low. Cluster 1 was rich in resting memory CD4 T cells, regulatory T cells, monocytes, and resting mast cells, and Cluster 2 was rich in activated memory CD4 T cells and follicular helper T cells. Thirteen IncRNAs were selected to construct a risk model, and the prognosis of gastric cancer patients in the high-risk group was poor. The expression of PD-L1 in tumours is significantly higher than that in normal tissues. Univariate and multivariate Cox regression analysis results showed that the overall survival rate was significantly related to stage and the risk score, which can be used as an independent prognostic factor. The results of the heatmap and scatter plot showed that clusters (P = 0.0045) and grade (G1–2, G3, P = 0.0037) were significantly related to prognosis. The relationship between the risk score and immune cell infiltration showed that memory B cells, resting dendritic cells, M0 macrophages, and M2 macrophages were positively correlated with the risk score, while resting mast cells, monocytes, activated NK cells, and follicular helper T cells were negatively correlated with the risk score.

Conclusion: The results of this study indicate that m6A-related IncRNAs may play an important role in the prognosis of gastric cancer patients and the tumour immune microenvironment and may provide help for the treatment of gastric cancer patients.

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

*Correspondence: drtianyunhong@126.com

¹ Department of General Surgery, The Affiliated Nanchong Central Hospital of North Sichuan Medical College (University), Nanchong 637000, Sichuan, China

Full list of author information is available at the end of the article
Background
In recent years, with the advancement of medical standards and the popularization of health concepts, the global morbidity and mortality of gastric cancer have declined, but it is still a major public health problem [1]. Gastric cancer is the fourth most common cancer and the second leading cause of cancer death in the world [2], with approximately 738,000 deaths every year [3]. As a common RNA modification, m6A exists in IncRNAs and microRNAs and plays an important role in regulating the splicing and translation of IncRNAs [4–6]. In recent years, many studies have shown that the tumour microenvironment plays an important role in cancer progression [7–10]. Studies have shown that m6A modification is closely related to the tumour microenvironment and PD-L1 expression in hepatocellular carcinoma and cholangiocarcinoma [11–14], and prognostic models of m6A-related IncRNAs can be used to predict the overall survival of patients with various tumours [15–20], but the clinical application and immunotherapy effect of m6A-related IncRNAs in the prognosis of gastric cancer are still unclear.

This study aims to evaluate the correlation of m6A-related IncRNAs with immune cell infiltration and the prognosis of gastric cancer patients. By constructing a gastric cancer prognostic model, the patients were divided into high-risk and low-risk groups to determine whether m6A-related IncRNAs could be used as prognostic biomarkers for gastric cancer.

Materials and methods
Data collection
The clinically related information and IncRNA expression data of gastric cancer patients were downloaded from the TCGA database. The clinically related information mainly included sex, age, classification, grade, and TNM staging. Continuous variables were converted to categorical variables, and the chi-square test was used to compare the variables in the training group and validation group.

Identification of m6A-related genes and prognosis-related m6A IncRNAs
We extracted the expression matrix of m6A-related genes based on the mRNA expression data in the TCGA database, used the “Limma”R software package to filter m6A-related IncRNAs (P < 0.05, Cor > 0.5), and then visualized them as a coexpression network graph. Using univariate Cox regression analysis with P<0.05 as the screening standard, prognostic m6A-related IncRNAs were screened out. The Wilcoxon statistical method was used to detect the differential expression of IncRNAs between gastric cancer tissues and normal tissues.

Consensus clustering identifies m6A-related IncRNA subgroups
We used the “ConsensusClusterPlus” software package to cluster gastric cancer patients into different subtypes to explore the biological characteristics of m6A-related IncRNAs. Kaplan–Meier survival analysis and the log-rank test were used to analyse the differences in clinicopathological factors between the two groups.

The correlation between different clusters and the TIME was also explored. The “ESTIMATE” software package was used to calculate the stromal, ESTIMATE and immune scores, and the Wilcoxon test was used to test the differential expression of stromal, ESTIMATE and immune scores between the two clusters. The CIBERSORT algorithm was used to evaluate the immune cell type score of each sample. The Wilcoxon test was used to show the abundance of immune infiltrating cells between the two clusters.

Construction and validation of the risk model and its relationship with clinicopathological characteristics and immune cell infiltration
The least absolute shrinkage and selection operator (LASSO) regression algorithm was used to screen the m6A-related IncRNAs that are most closely related to overall survival. Then, a risk model was built. The formula for the risk score was coef1*1 + coef2*2 + ... + coefi*xi (where coef refers to the coefficient of each IncRNA, and X refers to the expression level of the IncRNA). According to the median risk score, the patients were divided into high-risk and low-risk groups. Kaplan–Meier survival analysis was used to detect the difference in overall survival between the high- and low-risk groups. According to clinicopathological characteristics, subgroup analysis, univariate Cox regression analysis and multivariate Cox regression analysis were performed to evaluate whether the risk score can be used as an independent prognostic factor. Pearson correlation tests were used to evaluate the relationship between the risk score and immune cell infiltration. This study was approved by the Ethic Committee of Nanchong Central Hospital (Fig. 1).
Results

Identification of m6A-related lncRNAs in gastric cancer (GC) patients

We extracted the expression of lncRNAs and m6A-related genes from the TCGA database and used Pearson’s correlation value > 0.5 and \( P < 0.01 \) as the criteria for screening m6A-related lncRNAs. The coexpression network of m6A-related lncRNAs is shown in Fig. 2A. Through univariate Cox regression analysis, 25 lncRNAs were obtained (\( P < 0.05 \)). The forest plot results showed that 12 lncRNAs were risk factors (HR > 1), and the remaining 13 lncRNAs were protective factors (HR < 1) (Fig. 2B). The heatmap and box plot show the expression of the 25 lncRNAs in gastric cancer tissues and normal tissues (Fig. 2C, D).

m6A-related lncRNA consensus clustering

Consensus clustering was used to cluster the samples, and the CDF curve showed that when \( k = 2 \), the interference between the subgroups was the smallest, and the difference was significant (Fig. 3A, B). According to the relative change in the area under the CDF curve and the tracking plot, the \( k \) value was determined to be 2 to 9 (Fig. 3C, D). The survival chart results showed that patients in the Cluster 2 subgroup had a higher overall survival rate (Fig. 3E, \( P < 0.05 \)).

Immune cell infiltration and tumour immune microenvironment (TIME) and genetic correlation analysis

We analysed the scores of 22 immune cell types, and the results showed that Cluster 1 was rich in resting memory CD4 T cells, regulatory T cells, monocytes, and resting mast cells (all \( P < 0.05 \)). Cluster 2 was rich in activated memory CD4 T cells and follicular helper T cells (Fig. 4A, all \( P < 0.05 \)). To further understand the relationship between m6A-related lncRNAs and immunity, the ESTIMATE algorithm was used to calculate the distribution difference of the immunity ratio. Cluster 1 had a higher ESTIMATE score, immune score and stromal score (Fig. 4B–D). The correlation between m6A-related lncRNAs showed that there was a positive correlation between these lncRNAs (Fig. 4E). The expression of PD-L1 in the two clusters was not significantly different (Fig. 4F). The expression of PD-L1 in tumour tissues was significantly higher than that in normal tissues (Fig. 4G).

Construction and verification of a prognostic model based on m6A-related lncRNAs

We used LASSO regression analysis to identify prognosis-related m6A lncRNAs (Fig. 5A, B). Based on the median risk score, we divided the gastric cancer patients into high-risk and low-risk groups. The survival analysis results showed that the survival rate of gastric cancer patients
patients in the high-risk group was poor (Fig. 5C, D). The risk score and survival status distribution results of each patient in the training group and the validation group showed that the higher the risk score was, the higher the patient's mortality rate and the more significantly reduced the survival time was. The heatmap showed that the expression patterns of 13 lncRNAs in the high- and low-risk groups were different (Fig. 5E, F). The above results indicate that the risk score based on 13 m6A-related lncRNAs has high predictive power for the prognosis of gastric cancer patients.

The prognostic risk score is related to clinicopathological characteristics and immune cell infiltration

We used univariate and multivariate Cox regression analyses to determine whether the risk model based on m6A-related lncRNAs can be used as an independent prognostic factor for predicting gastric cancer patient survival. Univariate Cox regression analysis showed that the overall survival rate was significantly related to stage and risk score. Stage (HR = 1.866, \( P < 0.001 \)) and risk score (HR = 1.587, \( P < 0.001 \)) were independent prognostic factors in the training group. The results of multivariate Cox regression analysis showed that age (HR = 1.027, \( P < 0.032 \)) and stage (HR = 1.412, \( P < 0.024 \)) were independent prognostic factors in the validation group. Stage (HR = 2.015, \( P < 0.001 \)) and risk score (HR = 1.666, \( P < 0.001 \)) were independent prognostic factors in the training group (Fig. 6A–D).

We further evaluated the relationship between the risk score and prognosis of 13 m6A-related lncRNAs. The results of the heatmap and scatter plot showed that clusters (\( P = 0.0045 \)) and grade (G1-2, G3, \( P = 0.0037 \)) were significantly related to prognosis (Fig. 7A–K).
further explored the relationship between the risk score and immune cell infiltration (Fig. 8A–H), and the results showed that memory B cells, resting dendritic cells, M0 macrophages, and M2 macrophages were positively correlated with the risk score (all $P < 0.01$), while resting mast cells, monocytes, activated NK cells, and follicular helper T cells were negatively correlated with the risk score (all $P < 0.01$).

**Discussion**

Characterized by its low early diagnosis rate, high malignancy and poor prognosis, GC is a serious threat to human health in our country. At present, the process of the malignant progression of GC has not been fully elucidated. The identification of new biomarkers for the diagnosis and prognosis of GC has become a prerequisite to successfully treat GC. Accumulating evidence indicates the significant influences of lncRNAs on tumorigenesis [21, 22]. LncRNAs impact various dimensions in the occurrence and progression of tumours, especially at the transcriptional and posttranscriptional levels [23]. For example, Ning Cui experimentally observed [24] that LINC00511 acted as a therapeutic target in GC treatment and could regulate the expression of STAT3 via miR-625-5p. LINC00649 functions as an oncogenic lncRNA by accelerating cell proliferation, migration and epithelial–mesenchymal transition [25]. With the continuous development of molecular biotechnology, IncRNAs related to GC have been discovered, but our understanding of them is still in rudimentary stages. As the most prevalent internal modification of RNA, m6A has been thoroughly and widely studied recently. Published reports
indicate that m6A-related lncRNAs could affect both the occurrence and progression of GC. Four m6A-methylated and expressed lncRNAs were identified, including RASAL2-AS1, LINC00910, SNHG7 and LINC01105, which exert regulatory roles on GC cell proliferation [26]. However, the prognostic significance of m6A-related lncRNAs needs to be further explored.

This study analysed m6A-related lncRNAs related to the clinical characteristics of gastric cancer patients and found that 12 lncRNAs were risk factors (HR > 1) and 13 lncRNAs were protective factors (HR < 1). The risk score constructed from 13 m6A-related lncRNAs was significantly related to overall survival, clusters and grade (G1–2, G3). Cluster 1 was related to the high-risk group, and its prognosis was poor.

M6A regulators, such as writers, readers and erasers, play important roles in cancer. Our results showed that 12 IncRNAs were risk factors (HR > 1), and 13 IncRNAs were protective factors (HR < 1) for gastric cancer. We constructed a risk score model based on thirteen m6A-related IncRNAs, including LINC00106, TYMSOS, MED8-AS1, SREBF2-AS1, AL390961.2, AC144546.1, and AC005586.1. Our results show that the risk model based on m6A-related IncRNAs is reliable. Wang and his colleagues found that the expression of LINC00106 in thyroid cancer was significantly lower than that in normal tissues. LINC00106 suppresses the metastasis and invasion of cancer cells by inhibiting epigenetic-mesogenic transition as a tumour suppressor [27]. A risk score model was developed based on five IncRNAs: LINC00205, TRHDE-AS1, OVAAL, LINC00106, and MIR100HG. Wu verified that this [28] IncRNA-based risk model performs well in predicting GC prognosis. LINC00106 could be regarded as a significant prognostic biomarker in gastric cancer [29], which was in agreement with the findings of our study. Studies have found [30] that TYMSOS is overexpressed in GC cells and exerts growth-promoting effects on GC. Moreover, TYMSOS, as a competitive endogenous RNA, modulates GC progression at the posttranscriptional level. Unlike the above mentioned investigations, the IncRNAs AL390961.2, AC144546.1, and AC005586.1 were first reported in GC, leaving a wide scope for further research.

Fig. 4 A The infiltrating levels of immune cell types in Cluster 1/2 subtypes. B ESTIMATE score in two subtypes. C Immune score in two subtypes. D Stromal score in two subtypes. E The correlation between m6A-related IncRNAs and PD-L1 and other genes. F PD-L1 expression in two clusters. G PD-L1 expression in tumor and normal tissues
A number of studies in recent years have shown that m6A can play an important role in cancer immunity through different regulatory factors [31–34]. The m6A regulatory factor in colon cancer has three m6A modification modes, and these three m6A modification modes are closely related to the immunophenotype [35]. The tumour immune microenvironment plays an important role in immunotherapy. It has been reported that tumour-infiltrating lymphocytes in the tumour microenvironment promote disease progression and increase the chance of invasion and metastasis. M2 macrophage infiltration is correlated with a poor prognosis in colon cancer [36]. Furthermore, a higher fraction of M0 macrophages \( (P=0.001) \) and a lower fraction of M2 macrophages \( (P=0.018) \) were found to be risk factors for a poorer histological grade of hepatocellular carcinoma [37]. Some studies have reported that tumour-associated macrophage infiltration is associated with invasion, angiogenesis, and poor prognosis in GC [38]. This study found that Cluster 2 was rich in activated memory
CD4 T cells and follicular helper T cells and has low activation in stromal cells. The results of the relationship between the risk score and immune cell infiltration showed that memory B cells, resting dendritic cells, M0 macrophages, and M2 macrophages were positively correlated with the risk score (all \( P < 0.01 \)), while resting mast cells, monocytes, activated NK cells, and follicular helper T cells were negatively correlated with the risk score (both \( P < 0.01 \)). In summary, we analysed stromal cells and infiltrating immune cells in the tumour immune microenvironment, and the results showed that m6A-related lncRNAs were involved in the reprogramming of the tumour immune microenvironment.

This study still has some limitations. First, the effectiveness of this model still needs to be verified in a large number of external samples. Second, the m6A-related lncRNAs selected in this study need to be verified by further functional experiments. It is necessary to further reveal the regulatory network between m6A and lncRNAs.

In conclusion, this study screened 25 m6A-related lncRNAs. Different gastric cancer patients have different lncRNA subtypes in terms of overall survival, and the overall survival of Cluster 2 is higher. The prognostic risk score of m6A-related lncRNAs is closely related to clinicopathological characteristics (grade), the two subtypes and immune cell infiltration.
Fig. 7  The prognostic risk score is related to clinicopathological characteristics. A Heat maps of clinicopathological characteristics, immune scores and different lncRNA expression patterns in the high and low-risk groups. B Distribution of risk scores stratified by age. C Distribution of risk scores stratified by Cluster 1/2. D Distribution of risk scores stratified by sex. E Distribution of risk scores stratified by grade. F Distribution of risk scores stratified by immune score. G Distribution of risk scores stratified by M stage. H Distribution of risk scores stratified by N stage. I Distribution of risk scores stratified by stage. J Distribution of risk scores stratified by T stage. K PD-L1 expression in high/low risk

Fig. 8  Relationship between the risk score and infiltration level of eight immune cell types. A B cells memory. B Dendritic cells resting. C Macrophage M0. D Macrophages M2. E Mast cells resting. F Monocytes. G NK cells activated. H T cells follicular helper
Abbreviations
GC: Gastric cancer; CDFs: Cumulative distribution functions; TIME: Tumor immune microenvironment; TCGA: The cancer genome atlas.

Acknowledgements
Not applicable.

Author contributions
All authors contributed to the study design as well as the collection and analysis of the data. JH, JS, and XL designed the research; SL, WH and ZS performed the clinical and basic research; JH, JS and YT performed the statistical analyses; YC, SK, and ZG drafted the work; SL and JH substantively revised it. All authors read and approved the final manuscript.

Funding
This work was supported by the Foundation of Health Commission of Sichuan Province [19PJ061], and Cooperative project of Nanchong City with North Sichuan Medical College [20XSQTX321]. The funding body has no role in the design of the study and collection, analysis, and interpretation of data and inwriting the manuscript.

Availability of data and materials
The datasets generated and analyzed during the current study are available in the TCGA repository, [https://www.cancer.gov/about-nci/organization/ccg/](https://www.cancer.gov/about-nci/organization/ccg/ research/structural-genomics/tpcga).

Declarations
Ethics approval and consent to participate
The research article was approved by the ethics committee of Nanchong Central Hospital and was carried out in accordance with the 1975 Helsinki Declaration. Because of the anonymous nature of the data and the opt-out option disclosed on our institution’s homepage, the requirement for additional informed consent to participate in this study was deemed unnecessary.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Department of General Surgery, The Affiliated Nanchong Central Hospital of North Sichuan Medical College (University), Nanchong 637000, Sichuan, China. 2 Clinical Research Group, Grade 2017 in Department of Clinical Medicine, North Sichuan Medical College (University), Nanchong 637000, Sichuan, China. 3 Clinical Research Group, Grade 2018 in Department of Clinical Medicine, North Sichuan Medical College (University), Nanchong 637000, Sichuan, China. 4 Clinical Research Group, Grade 2019 in Department of Clinical Medicine, North Sichuan Medical College (University), Nanchong 637000, Sichuan, China. 5 Department of Radiology, Wayne State University, Detroit, MI, USA.

Received: 18 October 2021 Accepted: 20 July 2022
Published online: 25 July 2022

References
1. Van Cutsem E, Sapaert X, Topal B, et al. Gastric cancer[J]. Lancet. 2016;388(10060):2654–64.
2. Crew KD, Neugut AI. Epidemiology of gastric cancer[J]. World J Gastroen- terol WJG. 2006;12(3):354.
3. Sitarz R, Skierucha M, Mielko J, et al. Gastric cancer: epidemiology, pre- vention, classification, and treatment[J]. Cancer Manag Res. 2018;10:239.
4. Dai F, Wu Y, Lu Y, et al. Crosstalk between RNA m6A modification and non-coding RNA contributes to cancer growth and progression[J]. Mol Ther Nucleic Acids. 2020;22:62.
5. Coker H, Wei G, Brockdorff N. m6A modification of non-coding RNA and the control of mammalian gene expression[J]. Biochim et Biophys Acta (BBA)-Gene Regul Mech. 2019;1862(3):310–8.
6. Lan Y, Liu B, Guo H. The role of m6A modification in the regulation of tumor related IncRNAs[J]. Mol Ther Nucleic Acids. 2021;24:768.
7. Binnewies M, Roberts EW, Kersten K, et al. Understanding the tumor immune microenvironment (TIME) for effective therapy[J]. Nat Med. 2018;24(5):541–50.
8. Keren L, Bosse M, Marquez D, et al. A structured tumor-immune microenviron- ment in triple negative breast cancer revealed by multiplexed ion beam imaging[J]. Cell. 2018;174(6):1373–87.
9. Taube JM, Klein A, Brahmner JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy[J]. Clin Cancer Res. 2014;20(19):5064–74.
10. Chen SMY, Kirsinsky AL, Woolaver RA, et al. Tumor immune microenvironment in head and neck cancers[J]. Mol Carcinog. 2020;59(7):766–74.
11. Shen S, Yan J, Zhang Y, et al. N6-methyladenosine (m6A)-mediated messen- ger RNA signatures and the tumor immune microenvironment can predict the prognosis of hepatocellular carcinoma[J]. Ann Transl Med. 2021;9(1):59.
12. Qiu X, Yang S, Wang S, et al. m6A demethylase ALKBHS regulates PD-L1 expression and tumor immuneinfiltration in intrahepatic cholangiocarcinoma[J]. Cancer Res. 2021;81:14778.
13. Li R, Yin YH, Ji XL, et al. Pan-cancer prognostic, immunity, stemness, and anticancer drug sensitivity characterization of N6-methyladenosine RNA modification regulators in human cancers[J]. Front Mol Biosci. 2021. [https://doi.org/10.3389/fmbio.2021.664620].
14. Li J, Wang W, Zhou Y, et al. m6A regulator-associated modification patterns and immune infiltration of the tumor microenvironment in hepatocarcinoma[J]. Front Cell Dev Biol. 2021;9:1679.
15. Wang H, Meng Q, Ma B. Characterization of the prognostic m6A-related IncRNA signature in gastric cancer[J]. Front Oncol. 2021;11:927.
16. Zheng J, Guo J, Cao B, et al. Identification and validation of IncRNAs involved in m6A regulation for patients with ovarian cancer[J]. Cancer Cell Int. 2021;21:1(1):1–18.
17. Yu H, Zhang Z. ALKBHS-mediated m6A demethylation of IncRNA RMRP plays an oncogenic role in lung adenocarcinoma[J]. Mamm Genome. 2021;32(3):195–203.
18. Li Z, Li Y, Zhang W, et al. m6A-related IncRNA to develop prognostic sign- nature and predict the immune landscape in bladder cancer[J]. J Oncol. 2021;2021:1–16.
19. Ji F, Lu Y, Chen S, et al. m6A methyltransferase METTL3-mediated IncRNA FOXD2-AS1 promotes the tumorigenesis of cervical cancer[J]. Mol Ther Oncolytics. 2021;22:574.
20. Wen S, Wei Y, Zen C, et al. Long non-coding RNA NEAT1 promotes bone metastasis of prostate cancer through N6-methyladenosine[J]. Mol Cancer. 2020;19(1):1–18.
21. Wang J, Su Z, Lu S, et al. LncRNA HOXA-AS2 and its molecular mecha- nisms in human cancer. Clin Chim Acta. 2018;485:229–33.
22. Bhan A, Soleimani M, Mandal SS. Long noncoding RNA and cancer: a new paradigm. Cancer Res. 2017;77(15):3965–81.
23. He RZ, Luo DX, Mo YY. Emerging roles of IncRNAs in the post-transcrip- tional regulation in cancer. Genes Dis. 2019;6(1):16–15.
24. Cui N, et al. Long non-coding RNA LINCO00511 regulates the expression of microRNA-625-5p and activates signal transducers and activators of transcription 3 (STAT3) to accelerate the progression of gastric cancer. Bioengineered. 2021;12(1):2915–27.
25. Wang H, et al. Long non-coding RNA LINCO00649 regulates YES- associated protein 1 (YAP1)/Hippo pathway to accelerate gastric cancer (GC) progression via sequestering miR-16-5p. Bioengineered. 2021;12(1):1791–802.
26. Lv Z, et al. Joint analysis of IncRNA m6A/methyle and IncRNA/mRNA expression profiles in gastric cancer. Cancer Cell Int. 2020;20:464.
27. Wang JX, et al. LINCO0106 prevents against metastasis of thyroid cancer by inhibiting epithelial-mesenchymal transition. Eur Rev Med Pharmacol Sci. 2020;24(19):10015–21.
28. Wu Y, et al. A risk score model with five long non-coding RNAs for predicting prognosis in gastric cancer: an integrated analysis combining TCGA and GEO datasets. PeerJ. 2021;9:e10556.
29. Qi M, et al. Integrated analysis of a ceRNA network reveals potential prognostic IncRNAs in gastric cancer. Cancer Med. 2020;9(5):1798–817.
30. Gu Y, et al. TYMSOS drives the proliferation, migration, and invasion of gastric cancer cells by regulating ZNF703 via sponging miR-4739. Cell Biol Int. 2021;45(8):1710–9.
31. Xu S, Tang L, Dai G, et al. Expression of m6A regulators correlated with immune microenvironment predicts therapeutic efficacy and prognosis in gliomas[J]. Front Cell Dev Biol. 2020;8:1335.
32. Du J, Ji H, Ma S, et al. m6A regulator-mediated methylation modification patterns and characteristics of immunity and stemness in low-grade glioma[J]. Brief Bioinf. 2021. https://doi.org/10.1093/bib/bbab013.
33. Fang J, Hu M, Sun Y, et al. Expression profile analysis of m6A RNA methylation regulators indicates they are immune signature associated and can predict survival in kidney renal cell carcinoma[J]. DNA Cell Biol. 2020;39(12):2194–211.
34. Wu XR, Chen Z, Liu Y, et al. Prognostic signature and immune efficacy of m1A-, m5C- and m6A-related regulators in cutaneous melanoma[J]. J Cell Mol Med. 2021;25:8405.
35. Chong W, Shang L, Liu J, et al. m6A regulator-based methylation modification patterns characterized by distinct tumor microenvironment immune profiles in colon cancer[J]. Theranostics. 2021;11(5):2201.
36. Bai R, et al. Pan-cancer analyses demonstrate that ANKRD6 is associated with a poor prognosis and correlates with M2 macrophage infiltration in colon cancer. Chin J Cancer Res. 2021;33(1):93–102.
37. Zhang Z, Wang Z, Huang Y. Comprehensive analyses of the infiltrating immune cell landscape and its clinical significance in hepatocellular carcinoma. Int J Gen Med. 2021;14:4695–704.
38. Ma YY, et al. Interaction of coagulation factors and tumor-associated macrophages mediates migration and invasion of gastric cancer. Cancer Sci. 2011;102(2):336–42.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.